Red blood cell surface biotinylation (RBC biotinylation)

Red blood cell surface biotinylation is a research and diagnostic methodology used to track the lifespan and kinetics of erythrocyte populations (Mock et al., 1999, Transfusion). This technique involves the covalent attachment of biotin to the surface proteins of red blood cells, typically via N-hydroxysuccinimide (NHS) esters, allowing for the identification of specific cell cohorts over time (Cohen et al., 2008, American Journal of Hematology). It is not a therapeutic target but rather a tool used to study hematologic conditions such as sickle cell disease, thalassemia, and various forms of anemia (Franco et al., 2013, American Journal of Hematology). By labeling cells in vivo or ex vivo, researchers can track their disappearance from circulation using flow cytometry and streptavidin-conjugated fluorophores. This method provides a safer, non-radioactive alternative to the traditional chromium-51 labeling technique for determining red blood cell lifespan. It is frequently employed in clinical trials to evaluate the efficacy of treatments aimed at improving red blood cell stability or to assess the quality of stored blood products. The labeling process is generally considered non-toxic and does not significantly alter the physiological behavior of the erythrocytes, though it requires precise technical execution to ensure uniform labeling.

Other names

In vivo biotinylation of erythrocytesBiotin labeling of red blood cellsErythrocyte population trackingRBC lifespan measurement

Not applicable as this is a diagnostic/research methodology. The process involves the covalent attachment of biotin to ε-amino groups of lysine residues on red blood cell surface proteins using N-hydroxysuccinimide (NHS) esters (Mock et al., 1999, Transfusion).